BATTER-UP Takes Swing at Potential RA Biomarkers

“The beautiful thing about this study is that it will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise,” says Dr. Gregersen . “There is so much technological advancement going on. The problem is always that you don’t have a well-defined cohort of patients to study with these new technologies. Now, we’ll have something in place not only for BATTER-UP, but for future biomarker studies.”

Sue Pondrom is a medical journalist based in San Diego.

Reference

Bienkowska JR, Dalgin GS, Batliwalla F, et al. Convergent random forest predictor: Methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics. 2009, 94:423-432.

WASHINGTON, D.C.—Calling it an extremely challenging topic, Peter K. Gregersen, MD, professor and head, Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute, Manhasset, N.Y., said the current role of genetics in clinical practice is less about how to use genetic information to care for patients and more about how providers and patients…

Biomarkers to assess disease progression are in use, but none can predict which therapy will work best for each patient

A career marked by scientific discovery, collaboration

Reckless approach versus missed opportunity?

Reference

Can Genetic Information Change the Clinical Care of Rheumatology Patients?

Biomarkers in Rheumatoid Arthritis Remain Elusive

Rheumatologist Lars Klareskog, MD, PhD, In the Spotlight

TNF Blockade for SLE

Reference

Related Articles